![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FGB |
Gene summary for FGB |
![]() |
Gene information | Species | Human | Gene symbol | FGB | Gene ID | 2244 |
Gene name | fibrinogen beta chain | |
Gene Alias | HEL-S-78p | |
Cytomap | 4q31.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P02675 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2244 | FGB | NAFLD1 | Human | Liver | NAFLD | 1.93e-11 | 1.09e+00 | -0.04 |
2244 | FGB | S41 | Human | Liver | Cirrhotic | 1.88e-02 | 4.12e-01 | -0.0343 |
2244 | FGB | S43 | Human | Liver | Cirrhotic | 4.22e-08 | 7.15e-01 | -0.0187 |
2244 | FGB | HCC1_Meng | Human | Liver | HCC | 2.41e-78 | 5.46e-01 | 0.0246 |
2244 | FGB | HCC2_Meng | Human | Liver | HCC | 5.55e-21 | -7.94e-01 | 0.0107 |
2244 | FGB | cirrhotic1 | Human | Liver | Cirrhotic | 4.24e-11 | -5.56e-01 | 0.0202 |
2244 | FGB | cirrhotic2 | Human | Liver | Cirrhotic | 1.05e-12 | -2.85e-01 | 0.0201 |
2244 | FGB | cirrhotic3 | Human | Liver | Cirrhotic | 8.31e-06 | -5.58e-01 | 0.0215 |
2244 | FGB | HCC1 | Human | Liver | HCC | 2.06e-30 | 6.10e+00 | 0.5336 |
2244 | FGB | HCC2 | Human | Liver | HCC | 2.70e-44 | 8.49e+00 | 0.5341 |
2244 | FGB | HCC5 | Human | Liver | HCC | 2.86e-02 | 3.45e+00 | 0.4932 |
2244 | FGB | Pt13.a | Human | Liver | HCC | 8.81e-80 | 7.72e-01 | 0.021 |
2244 | FGB | Pt13.b | Human | Liver | HCC | 1.41e-102 | 6.48e-01 | 0.0251 |
2244 | FGB | Pt13.c | Human | Liver | HCC | 6.07e-39 | 9.33e-01 | 0.0076 |
2244 | FGB | Pt14.a | Human | Liver | HCC | 5.16e-20 | 5.42e-01 | 0.0169 |
2244 | FGB | Pt14.b | Human | Liver | HCC | 1.36e-28 | 8.03e-01 | 0.018 |
2244 | FGB | Pt14.c | Human | Liver | HCC | 2.02e-15 | 8.00e-01 | 0.0054 |
2244 | FGB | Pt14.d | Human | Liver | HCC | 5.12e-47 | 6.99e-01 | 0.0143 |
2244 | FGB | S015 | Human | Liver | HCC | 1.02e-02 | 1.40e+00 | 0.2375 |
2244 | FGB | S016 | Human | Liver | HCC | 3.93e-04 | -6.22e-01 | 0.2243 |
Page: 1 2 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00610417 | Liver | NAFLD | regulation of wound healing | 39/1882 | 134/18723 | 5.52e-10 | 1.28e-07 | 39 |
GO:00420607 | Liver | NAFLD | wound healing | 84/1882 | 422/18723 | 6.56e-10 | 1.37e-07 | 84 |
GO:0042730 | Liver | NAFLD | fibrinolysis | 15/1882 | 25/18723 | 1.26e-09 | 2.30e-07 | 15 |
GO:0030195 | Liver | NAFLD | negative regulation of blood coagulation | 21/1882 | 49/18723 | 2.42e-09 | 4.05e-07 | 21 |
GO:1900047 | Liver | NAFLD | negative regulation of hemostasis | 21/1882 | 50/18723 | 3.78e-09 | 5.40e-07 | 21 |
GO:0030193 | Liver | NAFLD | regulation of blood coagulation | 24/1882 | 66/18723 | 9.30e-09 | 1.26e-06 | 24 |
GO:0050819 | Liver | NAFLD | negative regulation of coagulation | 21/1882 | 53/18723 | 1.33e-08 | 1.69e-06 | 21 |
GO:1900046 | Liver | NAFLD | regulation of hemostasis | 24/1882 | 68/18723 | 1.84e-08 | 2.09e-06 | 24 |
GO:0061045 | Liver | NAFLD | negative regulation of wound healing | 26/1882 | 78/18723 | 1.86e-08 | 2.09e-06 | 26 |
GO:19030347 | Liver | NAFLD | regulation of response to wounding | 41/1882 | 167/18723 | 4.70e-08 | 4.58e-06 | 41 |
GO:0050818 | Liver | NAFLD | regulation of coagulation | 24/1882 | 71/18723 | 4.80e-08 | 4.60e-06 | 24 |
GO:00226047 | Liver | NAFLD | regulation of cell morphogenesis | 62/1882 | 309/18723 | 8.35e-08 | 7.09e-06 | 62 |
GO:00075994 | Liver | NAFLD | hemostasis | 49/1882 | 222/18723 | 9.23e-08 | 7.59e-06 | 49 |
GO:00075964 | Liver | NAFLD | blood coagulation | 48/1882 | 217/18723 | 1.16e-07 | 8.81e-06 | 48 |
GO:00508174 | Liver | NAFLD | coagulation | 48/1882 | 222/18723 | 2.40e-07 | 1.61e-05 | 48 |
GO:00071606 | Liver | NAFLD | cell-matrix adhesion | 49/1882 | 233/18723 | 4.36e-07 | 2.74e-05 | 49 |
GO:00108107 | Liver | NAFLD | regulation of cell-substrate adhesion | 47/1882 | 221/18723 | 5.30e-07 | 3.16e-05 | 47 |
GO:0031639 | Liver | NAFLD | plasminogen activation | 12/1882 | 24/18723 | 8.76e-07 | 4.60e-05 | 12 |
GO:1903035 | Liver | NAFLD | negative regulation of response to wounding | 26/1882 | 94/18723 | 1.18e-06 | 5.66e-05 | 26 |
GO:00315896 | Liver | NAFLD | cell-substrate adhesion | 65/1882 | 363/18723 | 2.84e-06 | 1.18e-04 | 65 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FGB | SNV | Missense_Mutation | rs771728339 | c.1203N>A | p.Asn401Lys | p.N401K | P02675 | protein_coding | deleterious(0.03) | possibly_damaging(0.794) | TCGA-LA-A446-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FGB | SNV | Missense_Mutation | c.1112N>T | p.Ser371Leu | p.S371L | P02675 | protein_coding | deleterious(0) | possibly_damaging(0.475) | TCGA-CV-5979-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
FGB | SNV | Missense_Mutation | rs200112613 | c.1189N>G | p.Met397Val | p.M397V | P02675 | protein_coding | deleterious(0.01) | probably_damaging(0.977) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FGB | SNV | Missense_Mutation | novel | c.970N>A | p.Leu324Ile | p.L324I | P02675 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-KK-A8I5-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD |
FGB | SNV | Missense_Mutation | novel | c.1231N>T | p.Asp411Tyr | p.D411Y | P02675 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-Y6-A8TL-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 6 | Unknown | Unknown | SD |
FGB | SNV | Missense_Mutation | rs746024226 | c.370A>G | p.Arg124Gly | p.R124G | P02675 | protein_coding | deleterious(0.05) | benign(0.399) | TCGA-BR-4357-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
FGB | SNV | Missense_Mutation | c.984A>C | p.Lys328Asn | p.K328N | P02675 | protein_coding | deleterious(0) | benign(0.043) | TCGA-F1-6177-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FGB | SNV | Missense_Mutation | rs571624045 | c.221G>A | p.Arg74His | p.R74H | P02675 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-HU-A4G8-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
FGB | SNV | Missense_Mutation | novel | c.1019N>G | p.Leu340Arg | p.L340R | P02675 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-IN-AB1X-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | leucovorin | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | inhibitor | CHEMBL1201505 | FIBRINOLYSIN, HUMAN | |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | RECOMBINANT FACTOR IX FC FUSION PROTEIN | |||
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | HAEMATOXYLIN | HAEMATOXYLIN | ||
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | eptifibatide | EPTIFIBATIDE | 20938371 | |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | ALFIMEPRASE | ALFIMEPRASE | ||
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | abciximab | ABCIXIMAB | 20938371 | |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | tirofiban | TIROFIBAN | 20938371 | |
2244 | FGB | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, FIBRINOGEN, DRUGGABLE GENOME | METHYLTHIONINIUM CHLORIDE | METHYLTHIONINIUM CHLORIDE |
Page: 1 |